$0.49
1.60%
NYSE, Nov 18, 03:59 pm EST. Closed.
ISIN
US44486Q1031
Symbol
HUMA

Humacyte Stock price

$0.50
+0.10 24.66% 1M
-0.40 44.35% 6M
-0.46 47.94% YTD
-0.70 58.33% 1Y
-2.07 80.54% 3Y
-10.99 95.65% 5Y
-9.17 94.83% 10Y
-9.17 94.83% 20Y
NYSE, Closing price Wed, Nov 18 2026
-0.00 0.20%
ISIN
US44486Q1031
Symbol
HUMA
Industry

Is Humacyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,090 stocks worldwide.

Key metrics

Basic
Market capitalization
$139.2m
Enterprise Value
$125.5m
Net debt
positive
Cash
$79.9m
Shares outstanding
277.8m
Valuation
P/E
negative
P/S | estimate
65.6 | 32.5
EV/Sales | estimate
59.2 | 29.3
EV/FCF | ex SBC
negative | negative
P/B
4.5
Financial Health
Equity Ratio
2.7%
Return on Equity
-1,313.4%
ROCE
-108.4%
ROIC
-220.6%
Debt/Equity
2.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$10.7m | 505.2%
SBC as % of FCF
-
SBC Growth 1Y
32.7%
Share Count Growth 1Y
77.7%
Shareholder Yield
-77.7%
Financials
Revenue | estimate
$2.1m | $4.3m
EBITDA
$-126.2m
EBIT
$-133.4m
Net Income
$-96.7m
Free Cash Flow | ex SBC
$-97.6m | $-108.3m
Growth
Revenue | estimate
158.5% | 109.8%
EBITDA
-21.5%
EBIT
-20.0%
Net Income
-64.7%
Free Cash Flow
7.9%
Margin
Gross
-494.6%
EBITDA
-5,949.8%
EBIT
-6,290.6%
Net
-4,560.8%
Free Cash Flow | ex SBC
-4,599.7% | -5,104.6%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
10.2%
Employees
184
Rev per Employee
$10.0k

Humacyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Humacyte forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Humacyte forecast:

Buy
82%
Hold
18%

Humacyte Events

Past Events
NOV
10
Q3 2026 Earnings Call
8 days ago
AUG
12
Q2 2026 Earnings Call
3 months ago
JUN
15
Special Call - Humacyte, Inc.
5 months ago
MAY
13
Q1 2026 Earnings Call
6 months ago
APR
28
Special Call - Humacyte, Inc.
7 months ago
MAR
27
Q4 2025 Earnings Call
8 months ago
MAR
10
Barclays 28th Annual Global Healthcare Conference
8 months ago
MAR
4
TD Cowen 46th Annual Health Care Conference
9 months ago
NOV
12
Q3 2025 Earnings Call
about one year ago

Financial data from Humacyte

Jun '26
+/-
%
2.12 2.12
159% 159%
100%
- Direct Costs 13 13
3,403% 3,403%
595%
-10 -10
2,380% 2,380%
-495%
- Selling and Administrative Expenses 31 31
2% 2%
1,471%
- Research and Development Expense 69 69
15% 15%
3,277%
-126 -126
22% 22%
-5,953%
- Depreciation and Amortization 7.23 7.23
1% 1%
341%
EBIT (Operating Income) EBIT -133 -133
20% 20%
-6,294%
Net Profit -97 -97
65% 65%
-4,563%

In millions USD.

Don't miss a Thing! We will send you all news about Humacyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Humacyte Stock News

Neutral
GlobeNewsWire
●
2 days ago
– Analysis of ATEVs from 52 patients across five clinical trials, some implanted for more than five years, found minimal lipid buildup and no evidence of vulnerable plaques. – First long-term clinical evaluation of atherosclerosis susceptibility in a tissue engineered vessel.
Neutral
GlobeNewsWire
●
7 days ago
– Presentations include interim Phase 3 results in women, integrated outcomes from three Phase 3 dialysis access trials and long-term human explant data. – Podium presentation to provide an update on clinical results with Symvess® in military and civilian trauma settings.
More Humacyte News

Company Profile

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Head office United States
CEO Dr. Niklason
Employees 184
Founded 2004
Website humacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today